Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 350 clinical trials
PSMA/CD70 Bi-specific CAR-T Cell Therapy

The purpose of this study is to assess the feasibility, safety and efficacy of anti-PSMA/CD70 bi-specific CAR-T cell therapy in patients with CD70 and PSMA positive malignancies. Another goal of

  • 0 views
  • 11 Jul, 2022
  • 1 location
GD2/CD56 Bi-specific CAR-T Cell Therapy

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of anti-GD2/CD56 bi-specific CAR-T cell therapy in patients with GD2 and/or CD56 positive cancer. Another

  • 0 views
  • 14 Jul, 2022
  • 1 location
PD-L1 PET-imaging During CAR T-cell Therapy

receptor (CAR) T-cell therapy in a non-invasive manner. Moreover, within this trial 89Zr-atezolizumab PET/CT imaging as a tool to distinguish lymphoma activity from a treatment-related inflammatory signal

  • 0 views
  • 04 Oct, 2022
  • 1 location
RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma

RAPA-201-RRMM is an open-label, single-arm, non-randomized multicenter phase II study of RAPA-201 autologous T cells in adults with relapsed, refractory multiple myeloma who have received at least three (3) prior lines.

  • 1 views
  • 25 Mar, 2022
  • 1 location
Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma

This study evaluates the safety and efficacy of novel BCMA-targeted CAR-T cell therapy (CBG-002) for patients with relapsed or refractory multiple myeloma (r/r MM). CBG-002 is designed based on

  • 0 views
  • 15 Apr, 2021
  • 1 location
Anti-BCMA CAR T-Cell Therapy for R/R ITP

This is a prospective, single-center, open-label, single-arm study, to evaluate the efficacy and safety of Anti-BCMA chimeric antigen receptor T cell therapy(BCMA CAR-T)for patients with relapse

  • 0 views
  • 19 Apr, 2022
  • 1 location
CAR-T Cell Therapy Targeting to CD19 for R/R ALL

Refractory and relapsed (R/R) acute lymphoblastic leukemia (ALL) patients with active disease always have a dismal outcome. Chimeric antigen receptor (CAR) T-cell therapy targeting to Cluster of

  • 0 views
  • 03 Feb, 2022
  • 1 location
T CELL THERAPY OPPOSING NOVEL COVID-19 INFECTION IN IMMUNOCOMPROMISED PATIENTS (TONI)

This is an open label, phase I dose-escalation study to evaluate the safety of coronavirus-specific T cell (CST) therapy for prevention of SARS-CoV-2 infection in immunocompromised patients following hematopoietic stem cell transplantation (HSCT). Participants will receive donor-derived CSTs for prevention of SARS-CoV-2 infection after HSCT (≥28 days and <4 months …

  • 0 views
  • 07 Oct, 2022
  • 2 locations
NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer

NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer

  • 0 views
  • 24 Mar, 2022
  • 1 location
Pilot Study of Intravitreal Autologous CD34+ Stem Cell Therapy for Retinitis Pigmentosa (BMSCRP1)

In this Phase 1 open-labeled prospective study, one eye of each participant with vision loss from retinitis pigmentosa will be administered intravitreal injection of autologous CD34+ stem cells harvested from bone marrow. Each participant will be examined serially for 6 months after study injection to determine safety and feasibility of …

  • 4 views
  • 07 Oct, 2022
  • 1 location